177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 219 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Avapritinib for Advanced Systemic Mastocytosis June 17, 2021 How we are working with industry to translate research into real... April 26, 2022 Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... June 9, 2022 Load more HOT NEWS What to Do When You Are Diagnosed With Cancer During Pregnancy EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Cancer in My Community: Caring for the Whole Patient in Brazil FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous...
